Are We Ready for Biosimilars in Multiple Sclerosis? Experts Discuss Lessons From Other Immune-Mediated Diseases

What is the clinical use of biosimilars and how to best communicate with patients to avoid the nocebo effect?  Credit available for this activity expires: 3/29/24 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/990193?ecd=bdc_podcast_libsyn_mscpedu